Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO Study On Follow-On Biologics Focuses On Trade-Off Between Savings And R&D

This article was originally published in The Pink Sheet Daily

Executive Summary

Study extrapolates from CBO’s scoring of last year’s Senate bill to argue that “shorter exclusivity could lead to the worst of both worlds – fewer new biologics … and little savings.”

You may also be interested in...

Follow-On Biologics Would Increase Savings By 30 Percent With Coding Tweaks, CBO Says

Even without reimbursement changes, CBO estimates higher Medicare/Medicaid savings than in previous scoring of Senate bill.

Teva's Lucky Number Seven: Analysis Supports Shorter Exclusivity For Biologics

Paper by AEI fellow Brill challenges the assumptions in the 16-year estimate from Duke's Grabowski.

Pink Sheet Podcast: COVID-19 Vaccine Trial Stopped, Sponsor Filing Pledge, Rare Voucher Extended

Pink Sheet reporters and editor discuss the ramifications of the AstraZeneca vaccine trial hold and vaccine sponsors pledging to wait until the completion of Phase III before submitting applications, as well as efforts to extend the rare pediatric disease priority review voucher program.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts